RT Journal Article
SR Electronic
T1 Predicting SARS-CoV-2 variant spread in a completely seropositive population using semi-quantitative antibody measurements in blood donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.16.22276483
DO 10.1101/2022.06.16.22276483
A1 Buss, Lewis F
A1 Prete, Carlos A
A1 Whittaker, Charles
A1 Salomon, Tassila
A1 Oikawa, Marcio K.
A1 Pereira, Rafael H. M.
A1 Moura, Isabel C. G.
A1 Delerino, Lucas
A1 Franca, Rafael F. O.
A1 Miyajima, Fabio
A1 Mendrone-Junior, Alfredo
A1 de Almeida Neto, César
A1 Salles, Nanci A.
A1 Ferreira, Suzete C.
A1 Fladzinski, Karine A.
A1 de Souza, Luana M.
A1 Schier, Luciane K.
A1 Inoue, Patricia M.
A1 Xabregas, Lilyane A.
A1 Crispim, Myuki A. E.
A1 Fraiji, Nelson
A1 Carlos, Luciana M. B.
A1 Pessoa, Veridiana
A1 Ribeiro, Maisa A.
A1 de Souza, Rosenvaldo E.
A1 Cavalcante, Anna F.
A1 Valença, Maria I. B.
A1 da Silva, Maria V.
A1 Lopes, Esther
A1 Filho, Luiz A.
A1 Mateos, Sheila O. G.
A1 Nunes, Gabrielle T.
A1 Schlesinger, David
A1 da Silva, Sônia Mara Nunes
A1 Silva-Junior, Alexander L.
A1 Castro, Marcia C
A1 Nascimento, Vítor H.
A1 Dye, Christopher
A1 Busch, Michael P
A1 Faria, Nuno R
A1 Sabino, Ester C
YR 2022
UL http://medrxiv.org/content/early/2022/06/17/2022.06.16.22276483.abstract
AB Background SARS-CoV-2 serologic surveys estimate the proportion of the population with antibodies against historical variants which nears 100% in many settings. New analytic approaches are required to exploit the full information in serosurvey data.Method Using a SARS-CoV-2 anti-Spike (S) protein chemiluminescent microparticle assay, we attained a semi-quantitative measurement of population IgG titres in serial cross-sectional monthly samples of routine blood donations across seven Brazilian state capitals (March 2021-November 2021). In an ecological analysis (unit of analysis: age-city-calendar month) we assessed the relative contributions of prior attack rate and vaccination to antibody titre in blood donors. We compared blood donor anti-S titre across the seven cities during the growth phase of the Delta variant of concern (VOC) and use this to predict the resulting age-standardized incidence of severe COVID-19 cases.Results On average we tested 780 samples per month in each location. Seroprevalence rose to >95% across all seven capitals by November 2021. Driven proximally by vaccination, mean antibody titre increased 16-fold over the study. The extent of prior natural infection shaped this process, with the greatest increases in antibody titres occurring in cities with the highest prior attack rates. Mean anti-S IgG was a strong predictor (adjusted R2 =0.89) of the number of severe cases caused by the Delta VOC in the seven cities.Conclusions Semi-quantitative anti-S antibody titres are informative about prior exposure and vaccination coverage and can inform on the potential impact of future SARS-CoV-2 variants.Summary In the face of near 100% SARS-CoV-2 seroprevalence, we show that average semi-quantitative anti-S titre predicted the extent of the Delta variant’s spread in Brazil. This is a valuable metric for future seroprevalence studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Itau Unibanco Todos pela Saude program and by CADDE/FAPESP (MR/S0195/1 and FAPESP 18/14389 0) (http://caddecentre.org/); Wellcome Trust and Royal Society Sir Henry Dale Fellowship 204311/Z/16/Z (N.R.F.); the Gates Foundation (INV 034540 and INV 034652) the National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS, now in its fourth phase, REDS IV P) for providing the blood donor demographic and zip code data for analysis (grant HHSN268201100007I); and the UK Medical Research Council under a concordat with the UK Department for International Development and Community Jameel and the NIHR Health Protection Research Unit in Modelling Methodology. VHN was supported by CNPq (304714/2018-6). CAPJ was supported by FAPESP (2019/21858-0) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) Finance Code 001Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Brazilian national research ethics committee, CONEP CAAE - 30178220.3.1001.0068.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe serology data required to reporduce the analyses are available at the following repository https://github.com/CADDE-CENTRE. All other data are publically available.